Current approved anti-angiogenic therapies used in NSCLC consist of either monoclonal antibodies directed against VEGF-A (bevacizumab) and VEGFR2 (ramucirumab), or small-molecule tyrosine kinase inhibitors that bind proangiogenic factors’ receptors, such as the EMA-approved nintedanib which has a multi-targeted profile. This evidence concerns the gene KDR and non-small cell lung carcinoma.